Partnering
Collaborating to bring life-changing therapies to those in need
Focused on developing anti-infectives for immunocompromised patients, Aicuris is not limited to one proprietary platform or technology, and we look to identify novel approaches and opportunities that align with our focus and could benefit from our know-how. We are always open to discuss novel anti-virals and anti-fungals in late preclinical to clinical development, aiming to increase the quality of life of patients with low immune defenses. We are also open to discuss collaborative or different kinds of licensing discussions.
If you or your company are interested in partnering with Aicuris, please contact us at business@aicuris.com.
Our Partners
In 2012, Aicuris entered into an exclusive worldwide license agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) for its portfolio of investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (PREVYMIS®), that resulted in a successful registration of the drug in major markets.
In 2024, Aicuris and the DZIF entered a research collaboration and license option agreement under which the companies will jointly work on the identification of novel targets for antiviral therapies as well as the discovery of new active agents for the treatment and prophylaxis of infections of immunocompromised patients.
AiCubator
Fostering collaboration for anti-infectives
Often, it is not the lack of groundbreaking ideas that hinders the development of novel, innovative anti-viral drugs. Instead, it is a shortage of funding, development and business experience that limits resources for start-ups and research groups, thereby discouraging the development of new therapeutic options. At Aicuris, we strongly believe in the importance of fostering early-stage projects. Therefore, we are constantly seeking out novel technologies and creative approaches to develop more effective treatments against viral infections with high medical needs.
AiCubator Residents
Universitätsklinikum Hamburg-Eppendorf
There is currently no specific antiviral therapy against BKPyV, which causes severe disease in immunosuppressed patients. The project builds on a well-established workflow from phenotypic screening to mode of action (MoA) and will focus on key experiments to understand cytotoxicity and selectivity in infected primary cells and complex tissues to evaluate the inhibitor for further development.
Universitätsklinikum Erlangen
Researchers from the Institute for Clinical and Molecular Virology at the Universitätsklinikum Erlangen guided by Prof. Dr. Manfred Marschall in cooperation with academic partners at the Friedrich-Alexander University of Erlangen-Nürnberg, discovered unique structural and functional properties of the globular domain of the cytomegalovirus-specific nuclear egress complex (NEC), thereby nominating generally the herpesviral NECs as novel potential targets for therapy strategies against herpesvirus infections.